- Newer glucose-lowering drugs were associated with reduced cardiovascular risks in older adults with type 2 diabetes.
- The study included 35,679 individuals aged 70 and older.
- Both SGLT-2 inhibitors and GLP-1 receptor agonists showed significantly lower rates of major adverse cardiovascular events compared to dipeptidyl peptidase 4 inhibitors.
- The cardiovascular benefits were consistent across various subgroup analyses.
- The study did not assess safety outcomes.
- Authors highlighted the potential influence of the findings on guidelines for cardiovascular risk reduction in older adults with type 2 diabetes.
Source: eClinicalMedicine
